Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Colorectal Cancer (CRC) is one of the late complications observed in patients suffering from inflammatory bowel diseases (IBD). Carcinogenesis is promoted by persistent chronic inflammation occurring in IBD. Understanding the mechanisms involved is essential in order to ameliorate inflammation and prevent CRC. Thrombospondin 1 (TSP-1) is a multidomain glycoprotein with important roles in angiogenesis. The effects of TSP-1 in colonic tumor formation and growth were analyzed in a model of inflammation-induced carcinogenesis. WT and TSP-1 deficient mice (TSP-1-/-) of the C57BL/6 strain received a single injection of azoxymethane (AOM) and multiple cycles of dextran sodium sulfate (DSS) to induce chronic inflammation-related cancers. Proliferation and angiogenesis were histologically analyzed in tumors. The intestinal transcriptome was also analyzed using a gene microarray approach. When the area containing tumors was compared with the entire colonic area of each mouse, the tumor burden was decreased in AOM/DSS-treated TSP-1-/- versus wild type (WT) mice. However, these lesions displayed more angiogenesis and proliferation rates when compared with the WT tumors. AOM-DSS treatment of TSP-1-/- mice resulted in significant deregulation of genes involved in transcription, canonical Wnt signaling, transport, defense response, regulation of epithelial cell proliferation and metabolism. Microarray analyses of these tumors showed down-regulation of 18 microRNAs in TSP-1-/- tumors. These results contribute new insights on the controversial role of TSP-1 in cancer and offer a better understanding of the genetics and pathogenesis of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Also, several studies found a significant downregulation of TMIGD1 gene expression in diseases associated with chronic intestinal inflammation such as Crohn’s disease or inflammatory bowel disease26,73,77”
From Membrane recruitment of the polarity protein Scribble by the cell adhesion receptor TMIGD1 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Several unbiased studies describe a strong and highly significant reduction of TMIGD1 gene expression in colon cancer in humans72–75 with a progressive downregulation during disease progression21,76.”
From Membrane recruitment of the polarity protein Scribble by the cell adhesion receptor TMIGD1 (2023) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., Guernec, G., Martin, D., Merkel, A., Knowles, D. G., et al. (2012) · Genome Research · doi:10.1101/gr.132159.111 · Cited by 5,061
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo
Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M. F., Lawler, J., Hynes, R. O., Boivin, G. P., & Bouck, N. (1998) · Cell · doi:10.1016/s0092-8674(00)81460-9 · Cited by 1,174
Self-citationAugmentation of tumor angiogenesis by a Myc-activated microRNA cluster
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., et al. (2006) · Nature Genetics · doi:10.1038/ng1855 · Cited by 1,047
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736
Fazio, V., Robertis, M., Massi, E., Poeta, M., Carotti, S., Morini, S., Cecchetelli, L., & Signori, E. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.78279 · Cited by 579
Barsyte-Lovejoy, D., Lau, S. K., Boutros, P. C., Khosravi, F., Jurisica, I., Andrulis, I. L., Tsao, M. S., & Penn, L. Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0037 · Cited by 461
Cheng, H., Zhang, L., Cogdell, D. E., Zheng, H., Schetter, A. J., Nykter, M., Harris, C. C., Chen, K., Hamilton, S. R., & Zhang, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017745 · Cited by 430
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2561 · Cited by 305
Thrombospondin-1: Multiple Paths to Inflammation
Lopez-Dee, Z., Pidcock, K., & Gutierrez, L. S. (2011) · Mediators of Inflammation · doi:10.1155/2011/296069 · Cited by 283
Self-citationStreit, M., Velasco, P., Brown, L. F., Skobe, M., Richard, L., Riccardi, L., Lawler, J., & Detmar, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65140-1 · Cited by 279
Self-citationMethylation and silencing of the Thrombospondin-1 promoter in human cancer
Li, Q., Ahuja, N., Burger, P. C., & Issa, J.-P. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202663 · Cited by 171
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 168
Self-citationChu, L.-Y., Ramakrishnan, D. P., & Silverstein, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-482315 · Cited by 167 · cited 1×
“The suppression of VEGFR2 phosphorylation is accomplished by the binding of SHP-1 (SRC homology 2 domain containing protein tyrosine phosphatase 1) with the VEGFR2/CD36 signaling complex [3].”
BackgroundThrombospondin, a potentiator of tumor cell metastasis.
Tuszynski, G. P., Gasic, T. B., Rothman, V. L., Knudsen, K. A., & Gasic, G. (1987) · PubMed · Cited by 166
Matrix-bound thrombospondin promotes angiogenesis in vitro
Nicosia, R., & Tuszynski, G. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.183 · Cited by 165
p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers
Sundaram, P., Hultine, S., Smith, L. M., Dews, M., Fox, J. L., Biyashev, D., Schelter, J. M., Huang, Q., Cleary, M. A., Volpert, O. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1124 · Cited by 161
Lan, Y., Ovitt, C. E., Cho, E.-S., Maltby, K. M., Wang, Q., & Jiang, R. (2004) · Development · doi:10.1242/dev.01175 · Cited by 160
Kaur, S., Soto-Pantoja, D. R., Stein, E. V., Liu, C., Elkahloun, A. G., Pendrak, M. L., Nicolae, A., Singh, S. P., Nie, Z., Levens, D., et al. (2013) · Scientific Reports · doi:10.1038/srep01673 · Cited by 141
Differential Angiogenic Regulation of Experimental Colitis
Chidlow, J. H., Langston, W., Greer, J. J. M., Ostanin, D. V., Abdelbaqi, M. Q., Houghton, J., Senthilkumar, A., Shukla, D., Mazar, A. P., Grisham, M. B., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051021 · Cited by 141
The effect of thrombospondin-1 on breast cancer metastasis
Yee, K. O., Connolly, C. M., Duquette, M. A., Kazerounian, S., Washington, R. W., & Lawler, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9992-6 · Cited by 137
Self-citationThrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice
Lawler, J., Miao, W., Duquette, M. A., Bouck, N., Bronson, R. T., & Hynes, R. O. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63042-8 · Cited by 127
Self-citationSomatostatin receptors in human prostate and prostate cancer
Reubi, J. C., Waser, B., Schaer, J., & Markwalder, R. V. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673428 · Cited by 123
Bishayee, A., & Rabi, T. (2009) · Journal of Carcinogenesis · doi:10.4103/1477-3163.51368 · Cited by 121
Thrombospondin-1 Triggers Cell Migration and Development of Advanced Prostate Tumors
Firlej, V., Mathieu, J. R. R., Gilbert, C., Lemonnier, L., Nakhlé, J., Gallou‐Kabani, C., Guarmit, B., Morin, A., Prevarskaya, N. B., Delongchamps, N. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0833 · Cited by 103
Aust, D. E., Terdiman, J. P., Willenbucher, R. F., Chew, K., Ferrell, L. D., Florendo, C., Molinaro‐Clark, A., Baretton, G. B., Löhrs, U., & Waldman, F. M. (2001) · Modern Pathology · doi:10.1038/modpathol.3880253 · Cited by 98
Luo, Z., Zhang, L., Li, Z., Li, X., Li, G., Yu, H., Chen, J., Dai, Y., Guo, X., Xiang, J., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-3 · Cited by 98
Tanaka, T., Suzuki, R., Kohno, H., Sugie, S., Takahashi, M., & Wakabayashi, K. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh292 · Cited by 95
Kazerounian, S., Duquette, M. A., Reyes, M. A., Lawler, J. T., Song, K., Perruzzi, C. A., Primo, L., Khosravi‐Far, R., Bussolino, F., Rabinovitz, I., et al. (2011) · Blood · doi:10.1182/blood-2010-09-305284 · Cited by 83
Self-citationIdentification of CD36 molecular features required for its in vitro angiostatic activity
Primo, L., Ferrandi, C., Roca, C., Marchiò, S., Di Blasio, L., Alessio, M., & Bussolino, F. (2005) · The FASEB Journal · doi:10.1096/fj.05-3697fje · Cited by 78
Suzuki, R., Miyamoto, S., Yasui, Y., Sugie, S., & Tanaka, T. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-84 · Cited by 76
Dejong, V., Degeorges, A., Filleur, S., Ait‐Si‐Ali, S., Mettouchi, A., BORNSTEIN, P. K., Binétruy, B., & Cabon, F. (1999) · Oncogene · doi:10.1038/sj.onc.1202654 · Cited by 71
Punekar, S. R., Zak, S., Kalter, V. G., Dobransky, L., Punekar, I., Lawler, J., & Gutierrez, L. S. (2008) · Pathobiology · doi:10.1159/000113790 · Cited by 64
Self-citationThrombospondin-1 Is a Transcriptional Repression Target of PRMT6
Michaud‐Levesque, J., & Richard, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005322 · Cited by 64
Expression of angiostatic factors in colorectal cancer.
Yoshida, Y., Oshika, Y., Fukushima, Y., Tokunaga, T., Hatanaka, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., Miura, S., et al. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.6.1221 · Cited by 61
Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1.
Slack, J., & BORNSTEIN, P. K. (1994) · PubMed · Cited by 61
Somatostatin receptors in human prostate and prostate cancer
Reubi, J. C. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.9.2806 · Cited by 61
Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma
Zhou, L., Picard, D. J., Ra, Y., Li, M., Northcott, P. A., Hu, Y., Stearns, D. S., Hawkins, C. E., Taylor, M. D., Rutka, J. T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4562 · Cited by 60
Gutierrez, L. (2003) · Carcinogenesis · doi:10.1093/carcin/24.2.199 · Cited by 60
Self-citationThrombospondin-1 mediates oncogenic Ras–induced senescence in premalignant lung tumors
Baek, K.-H., Bhang, D., Zaslavsky, A., Wang, L.-C., Vachani, A., Kim, C. F., Albelda, S. M., Evan, G. I., & Ryeom, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67465 · Cited by 57
Talme, T., Ivanoff, J., Hägglund, M., van Neerven, R. J. J., Ivanoff, A., & Sundqvist, K. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01577.x · Cited by 55
Miyata, Y., & Sakai, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612249 · Cited by 51
Expression and role of thrombospondin-1 in colorectal cancer.
Miyanaga, K., Kato, Y. P., Nakamura, T., Matsumura, M., Amaya, H., Horiuchi, T., Chiba, Y., & Tanaka, K. (2002) · PubMed · Cited by 50
Oue, N., Matsumura, S., Nakayama, H., Kitadai, Y., Taniyama, K., Matsusaki, K., & Yasui, W. (2003) · Oncology · doi:10.1159/000070302 · Cited by 49
Müller, K. M., Tveteraas, I. H., Aasrum, M., Ødegård, J., Dawood, M., Dajani, O. F., Christoffersen, T., & Sandnes, D. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-421 · Cited by 49
Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model
Borinstein, S. C., Conerly, M. L., Dzieciatkowski, S., Biswas, S., Washington, M. K., Trobridge, P. A., Henikoff, S., & Grady, W. M. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20581 · Cited by 48
The miR-1-NOTCH3-Asef Pathway Is Important for Colorectal Tumor Cell Migration
Furukawa, S., Kawasaki, Y., Miyamoto, M., Hiyoshi, M., Kitayama, J., & Akiyama, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080609 · Cited by 47
Menschikowski, M., Hagelgans, A., Schuler, U. S., Froeschke, S., Rosner, A., & Siegert, G. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9652-y · Cited by 46
Protein expression analysis of inflammation-related colon carcinogenesis
Tanaka, T., & Yasui, Y. (2009) · Journal of Carcinogenesis · doi:10.4103/1477-3163.51851 · Cited by 45
Mojica, W., & Hawthorn, L. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-5 · Cited by 43
Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model.
Nambiar, P. R., Giardina, C. A., Guda, K., Aizu, W., Raja, R. G., & Rosenberg, D. W. (2002) · PubMed · Cited by 43
Bugni, J. M., Alrabadi, L. S., Jubbal, K. T., Karagiannides, I., Lawson, G. W., & Pothoulakis, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.26208 · Cited by 38
Colitis-accelerated colorectal cancer and metabolic dysregulation in a mouse model
Gao, Y., Li, X., Yang, M. W., Zhao, Q., Liu, X., Wang, G., Lü, X., Wu, Q., Wu, J., Yang, Y., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt135 · Cited by 36
Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease
Zak, S., Treven, J., Nash, N., & Gutierrez, L. S. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-007-0397-5 · Cited by 35
Self-citationEnhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane
Tasuta, M., Iishi, H., Baba, M., & Taniguchi, H. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.299 · Cited by 31
Regulatory factor X4 variant 3: A transcription factor involved in brain development and disease
Zhang, D., Zeldin, D. C., & Blackshear, P. J. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21356 · Cited by 30
Bossard, C., Souazé, F., Jarry, A., Bezieau, S., Mosnier, J., Forgez, P., & LABOISSE, C. L. (2007) · Peptides · doi:10.1016/j.peptides.2007.06.030 · Cited by 30
Thrombospondin-1 and VEGF in inflammatory bowel disease
Alkim, C. A., Sakız, D., Alkım, H., Livaoğlu, A., Kendir, T., Demirsoy, H., Erdem, L., Akbayır, N., & Sökmen, M. (2012) · Libyan Journal of Medicine · doi:10.3402/ljm.v7i0.8942 · Cited by 25
Dogar, A. M., Semplicio, G., Guennewig, B., & Hall, J. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0467 · Cited by 23
Lopez-Dee, Z. P., Chittur, S. V., Patel, B., Stanton, R., Wakeley, M. E., Lippert, B., Menaker, A., Eiche, B., Terry, R., & Gutierrez, L. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034590 · Cited by 21
Self-citationDefective processing of the transforming growth factor‐β1 in azoxymethane‐induced mouse colon tumors
Guda, K., Claffey, K. P., Dong, M., Nambiar, P. R., & Rosenberg, D. W. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10120 · Cited by 15
Gui, X. S., Liu, S., Yan, Y., & Gao, Z. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i28.4504 · Cited by 14
Kerr, C. A., Hines, B. M., Shaw, J. M., Dunne, R. A., Bragg, L. M., Clarke, J. M., Lockett, T. J., & Head, R. J. (2013) · BMC Physiology · doi:10.1186/1472-6793-13-2 · Cited by 13
Law, I. K. M., & Pothoulakis, C. (2015) · RNA & DISEASE · doi:10.14800/rd.472 · Cited by 7
Kawai, S., & Amano, A. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.064 · Cited by 5
Bobisse, S., Rondina, M., Merlo, A., et al. (2008) · Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) · doi:10.1158/0008-5472 · Cited by 1
Cited by
Functions of Thrombospondin-1 in the Tumor Microenvironment
Kaur, S., Bronson, S. M., Pal-Nath, D., Miller, T. W., Soto-Pantoja, D. R., & Roberts, D. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094570 · Cited by 173
Thrombospondin-1 is a multifaceted player in tumor progression
Huang, T., Sun, L., Yuan, X., & Qiu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19165 · Cited by 158
Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?
Tse, J. W. T., Jenkins, L. J., Chionh, F. J. M., & Mariadason, J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.003 · Cited by 148
Thrombospondin 1 in Metabolic Diseases
Gutierrez, L. S., & Gutierrez, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.638536 · Cited by 108
Self-citationIsenberg, J. S., & Roberts, D. D. (2020) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/70774 · Cited by 105
Metadata
- Authors
- Lopez-Dee, Z. P., Chittur, S. V., Patel, H., Chinikaylo, A., Lippert, B., Patel, B., Lawler, J., & Gutierrez, L. S.
- Affiliations
- Wilkes University (US)
- State University of New York (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Gutierrez, Linda S.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-13
- Volume
- 10
- Issue
- 10
- Pages
- e0139918
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4603676
- OpenAlex
- W2182444644
- Cited by
- 23
- References
- 70
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 6
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute
- Wilkes University
- National Institutes of Health (52006328)
- National Institute of Diabetes and Digestive and Kidney Diseases (R15DK067901)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- thrombospondin-1, colorectal cancer, inflammatory bowel disease, inflammation-induced carcinogenesis, angiogenesis, tumor cell proliferation, intestinal transcriptome, Wnt signaling, microRNA downregulation, chronic inflammation
- MeSH terms
- Animals, Azoxymethane, Colon, Disease Models, Animal, Immunohistochemistry, Inflammation, Mice, Inbred C57BL, RNA, Messenger, Colorectal Neoplasms, Reproducibility of Results, Down-Regulation, Up-Regulation, Gene Expression Regulation, Neoplastic, Dextran Sulfate, Thrombospondin 1, Cell Proliferation, Genes, Neoplasm, Microvessels, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.